AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 788855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no graded compression)
Number of subjects: 98
Study 31937181 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta neurofeedback training (12-22 Hz) for 20 sessions of 30 minutes each on the Cz site
Number of subjects: 0
Study 31937181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neurofeedback training)
Number of subjects: 0
Study 31237134 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-FAs 4,000 mg plus atorvastatin 20 mg
Number of subjects: 200
Study 31237134 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg plus placebo
Number of subjects: 200
Study 31030590 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic HPV vaccination
Number of subjects: 0
Study 31030590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28039060 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral calcium supplementation
Number of subjects: 106
Study 28039060 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 106
Study 25365032 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated carbohydrate gel (CC) - 21.6 g carbohydrate, 100 mg caffeine
Number of subjects: 13
Study 25365032 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-only placebo gel (CP) - 21.6 g carbohydrate, 0 mg caffeine
Number of subjects: 13
Study 23866306 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 808
Study 23866306 — intervention group
Group type: COMPARATOR
Intervention: doubling the baseline statin dose (simvastatin 40 mg or atorvastatin 20 mg)
Number of subjects: 808
Study 23866306 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg
Number of subjects: 808
Study 21894686 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian-harmonization group (group A)
Number of subjects: 150
Study 21894686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zang-organ regulation group (group B)
Number of subjects: 150
Study 21894686 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian-harmonization and zang-organ regulation group (group C)
Number of subjects: 150
Study 19125756 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (120,000 IU each; three doses, administered fortnightly)
Number of subjects: 100
Study 19125756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 17291720 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic), 200 microg Cr/d
Number of subjects: 83
Study 17291720 — intervention group
Group type: COMPARATOR
Intervention: Picolinic acid (1720 microg)
Number of subjects: 83
Study 17291720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15673989 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 75
Study 15673989 — intervention group
Group type: COMPARATOR
Intervention: SP6 touch control
Number of subjects: 75
Study 11697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (200-600 mg/day)
Number of subjects: 114
Study 11697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-30 mg/day)
Number of subjects: 114
Study 11697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (8-16 mg/day)
Number of subjects: 114
Study 11697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (10-40 mg/day)
Number of subjects: 114
Study 11697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (600-1600 mg/day)
Number of subjects: 114
Study 11697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free state
Number of subjects: 114
Study 11697576 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 114
Study 9215169 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 24
Study 9215169 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 24
Study 9215169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 8426714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam with nitrous oxide
Number of subjects: 0
Study 8426714 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 8426714 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (mean dose = 19.3 mg)
Number of subjects: 0
Study 3618574 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital for five days
Number of subjects: 238
Study 3618574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 3618574 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 238
Study 29742145 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral backpack (UB) carrying (12.5% body weight)
Number of subjects: 9
Study 29742145 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral backpack (UB) carrying
Number of subjects: 9
Study 29742145 — intervention group
Group type: COMPARATOR
Intervention: No backpack (NB)
Number of subjects: 9
Study 26468897 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 877
Study 26468897 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 877
Study 25917574 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20mg
Number of subjects: 521
Study 25917574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 23596051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (Gb) treatment
Number of subjects: 190
Study 23596051 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal subjects
Number of subjects: 190
Study 23596051 — intervention group
Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) subjects
Number of subjects: 190
Study 23596051 — intervention group
Group type: COMPARATOR
Intervention: APOE*4 allele presence
Number of subjects: 190
Study 23596051 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal and MCI subjects combined
Number of subjects: 190
Study 23596051 — intervention group
Group type: COMPARATOR
Intervention: Long-term exposure to Gb
Number of subjects: 190
Study 20875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% protein preload (1675 kJ)
Number of subjects: 0
Study 20875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% protein preload (1675 kJ)
Number of subjects: 0
Study 20875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% protein preload (1675 kJ)
Number of subjects: 0
Study 20875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% protein preload (1047 kJ)
Number of subjects: 0
Study 20875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% protein preload (1047 kJ)
Number of subjects: 0
Study 20875183 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% protein preload (1047 kJ)
Number of subjects: 0
Study 20875183 — intervention group
Group type: COMPARATOR
Intervention: Control (flavoured water preload)
Number of subjects: 0
Study 18254761 — intervention group
Group type: EXPERIMENTAL
Intervention: IN morphine 3.75 mg, 7.5 mg, 15 mg, or 30 mg
Number of subjects: 187
Study 18254761 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine 7.5 mg
Number of subjects: 187
Study 18254761 — intervention group
Group type: EXPERIMENTAL
Intervention: IN morphine 7.5 mg
Number of subjects: 187
Study 18254761 — intervention group
Group type: EXPERIMENTAL
Intervention: IN morphine 15 mg
Number of subjects: 187
Study 18254761 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine
Number of subjects: 187
Study 18254761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 16689066 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strip
Number of subjects: 48
Study 16689066 — intervention group
Group type: COMPARATOR
Intervention: 6.5% hydrogen peroxide whitening strip
Number of subjects: 48
Study 15301625 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who lost a competition to atypical men or women
Number of subjects: 0
Study 15301625 — intervention group
Group type: COMPARATOR
Intervention: Participants who lost a competition to typical men or women
Number of subjects: 0
Study 15301625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender deviants fearing backlash
Number of subjects: 0
Study 15301625 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceivers who sabotaged deviants (Experiment 2)
Number of subjects: 0
Study 15301625 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviants who hid their atypicality (Experiment 3)
Number of subjects: 0
Study 11220430 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) of oral transmucosal midazolam mixed with strawberry syrup
Number of subjects: 44
Study 11220430 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received plain syrup 0.08 ml x kg(‐1)
Number of subjects: 44
Study 11220430 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) of oral transmucosal midazolam
Number of subjects: 44
Study 9283123 — intervention group
Group type: EXPERIMENTAL
Intervention: Relactation with motivation, support, and repeated suckling
Number of subjects: 50
Study 9283123 — intervention group
Group type: COMPARATOR
Intervention: Relactation with motivation, support, repeated suckling, and metoclopramide (Group II)
Number of subjects: 50
Study 8193524 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix controlled clonidine transdermal (C‐TD) system
Number of subjects: 905
Study 8193524 — intervention group
Group type: COMPARATOR
Intervention: Membrane controlled clonidine system (C‐TTS)
Number of subjects: 905
Study 2419009 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Number of subjects: 202
Study 2419009 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 1,500,000 IU over 60 min
Number of subjects: 202
Study 2419009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 29451020 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study 29451020 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib, ceritinib, and alectinib (previous treatments)
Number of subjects: 0
Study 29894611 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO₂ 100%
Number of subjects: 71
Study 29894611 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO₂ 70%
Number of subjects: 71
Study 29894611 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO₂ 50%
Number of subjects: 71
Study 29894611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model based on seven bedside tests
Number of subjects: 71
Study 29894611 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO₂ 50-60%
Number of subjects: 71
Study 23866092 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative acupoint stimulation (IAS) - auricular acupressure combined with transcutaneous electric acupoint stimulation (TEAS) at the true acupoint
Number of subjects: 135
Study 23866092 — intervention group
Group type: COMPARATOR
Intervention: Sham group - acupoint stimulation at a sham acupoint or without embedding seeds and pressure
Number of subjects: 135
Study 23866092 — intervention group
Group type: COMPARATOR
Intervention: Control group - no IAS intervention
Number of subjects: 135
Study 23866092 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative acupoint stimulation (IAS)
Number of subjects: 135
Study 22396387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active conservative treatment for urinary incontinence (UI)
Number of subjects: 853
Study 19628566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 564
Study 19628566 — intervention group
Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 564
Study 18469351 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (ICL670)
Number of subjects: 49
Study 18469351 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 49
Study 18469351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49
Study 16882049 — intervention group
Group type: EXPERIMENTAL
Intervention: Double J 6-Fr polyurethane stents placed for 3 weeks (Group A)
Number of subjects: 56
Study 16882049 — intervention group
Group type: COMPARATOR
Intervention: Non-stented patients (Group B)
Number of subjects: 56
Study 12942573 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 0
Study 12942573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 0
Study 12942573 — intervention group
Group type: COMPARATOR
Intervention: Imipenem or Cefepime
Number of subjects: 0
Study 12942573 — intervention group
Group type: COMPARATOR
Intervention: Imipenem or Cefepime with vancomycin or amikacin
Number of subjects: 0
Study 10381164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial Electrical Stimulation (CES) for 20 minutes
Number of subjects: 52
Study 10381164 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 52
Study 8896856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP[+])
Number of subjects: 40
Study 8896856 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure (CP[-])
Number of subjects: 40
Study 1653711 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure mask physiotherapy (PEP)
Number of subjects: 7
Study 1653711 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced expiration technique combined with postural drainage (FET/PD)
Number of subjects: 7
Study 1653711 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study 6500759 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline micropellets (Euphyllin CR 350)
Number of subjects: 12
Study 6500759 — intervention group
Group type: COMPARATOR
Intervention: Theophylline micropellets
Number of subjects: 12
Study 31248863 — intervention group
Group type: EXPERIMENTAL
Intervention: dT1
Number of subjects: 123
Study 31248863 — intervention group
Group type: COMPARATOR
Intervention: 2D manual delineation
Number of subjects: 123
Study 30081948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: six sessions, three exercises, two sets; includes additional perturbations.
Number of subjects: 0
Study 30081948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: six sessions, two exercises, two sets; includes additional perturbations.
Number of subjects: 0
Study 30081948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: six sessions, one exercise, three sets; includes additional perturbations.
Number of subjects: 0
Study 30081948 — intervention group
Group type: COMPARATOR
Intervention: Control group: standardized exercise program of four sensorimotor exercises (three sets of 10 repetitions) in each of six training sessions (30 min duration) over 3 weeks.
Number of subjects: 0
Study 27033959 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D power Doppler (3DPD) angiography with five different machine settings
Number of subjects: 112
Study 27033959 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D power Doppler (3DPD) angiography
Number of subjects: 112
Study 24274799 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectation group
Number of subjects: 60
Study 24274799 — intervention group
Group type: COMPARATOR
Intervention: Negative expectation group
Number of subjects: 60
Study 22323351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 16
Study 22323351 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (AS)
Number of subjects: 16
Study 20172565 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 94
Study 20172565 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy
Number of subjects: 94
Study 20172565 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 94
Study 17382108 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone (DEX)
Number of subjects: 68
Study 17382108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16389695 — intervention group
Group type: EXPERIMENTAL
Intervention: Female model (young or old)
Number of subjects: 40
Study 16389695 — intervention group
Group type: COMPARATOR
Intervention: Male model (young or old)
Number of subjects: 40
Study 16389695 — intervention group
Group type: EXPERIMENTAL
Intervention: Model gender influence
Number of subjects: 40
Study 16389695 — intervention group
Group type: EXPERIMENTAL
Intervention: Model age influence
Number of subjects: 40
Study 16389695 — intervention group
Group type: EXPERIMENTAL
Intervention: Model gender influence on exercise form
Number of subjects: 40
Study 12049567 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 rad (5 Gy) irradiation at 1 minute post-treatment
Number of subjects: 27
Study 12049567 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 rad (5 Gy) irradiation at 2 minutes post-treatment
Number of subjects: 27
Study 12049567 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 rad (5 Gy) irradiation at 3 minutes post-treatment
Number of subjects: 27
Study 10607256 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Talpha1) 1.6 mg, twice weekly for 6 months
Number of subjects: 97
Study 10607256 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice weekly for 6 months
Number of subjects: 97
Study 8578549 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (ASA)
Number of subjects: 34
Study 8578549 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 34
Study 8578549 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 34
Study 2338114 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 600 mg
Number of subjects: 6
Study 2338114 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 6
Study 2338114 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 7002356 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 303
Study 7002356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 31151446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track assessment in medical examination chairs
Number of subjects: 3632
Study 27813347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) rehabilitation protocol
Number of subjects: 162
Study 27813347 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity (LI) rehabilitation protocol
Number of subjects: 162
Study 27813347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HI and LI interventions
Number of subjects: 162
Study 27183124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 14
Study 27183124 — intervention group
Group type: COMPARATOR
Intervention: Continuous Aerobic Exercise (CONT)
Number of subjects: 14
Study 23895200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determination theory (SDT) constructs including family routines, confidence, and importance
Number of subjects: 168
Study 21822627 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization strategies
Number of subjects: 0
Study 21822627 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mobile voluntary counseling and testing and post-test support services
Number of subjects: 0
Study 19828937 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic treatment
Number of subjects: 135
Study 19828937 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 135
Study 17551297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103
Number of subjects: 263
Study 17551297 — intervention group
Group type: COMPARATOR
Intervention: I-125
Number of subjects: 263
Study 17551297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isotopes
Number of subjects: 263
Study 11964644 — intervention group
Group type: EXPERIMENTAL
Intervention: Collared HD-II femoral component
Number of subjects: 84
Study 11964644 — intervention group
Group type: COMPARATOR
Intervention: Collarless HD-II femoral component
Number of subjects: 84
Study 11964644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 9655654 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17‐beta‐oestradiol (100 microg per 24 h)
Number of subjects: 13
Study 9655654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7865266 — intervention group
Group type: EXPERIMENTAL
Intervention: PDP (foam pressure dispersing pads) worn throughout hospitalization
Number of subjects: 54
Study 7865266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PDP)
Number of subjects: 54
Study 2644049 — intervention group
Group type: COMPARATOR
Intervention: 40 per cent O2 venturi masks
Number of subjects: 161
Study 2644049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal catheters
Number of subjects: 161
Study 2644049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal catheters and 40 per cent O2 masks
Number of subjects: 161
Study 29497859 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar transurethral resection (mTURB)
Number of subjects: 52
Study 29497859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection (bTURB)
Number of subjects: 52
Study 27600829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + MTX
Number of subjects: 1197
Study 27600829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + MTX
Number of subjects: 1197
Study 27600829 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 1197
Study 27600829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (both doses)
Number of subjects: 1197
Study 25661064 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A
Number of subjects: 35
Study 25661064 — intervention group
Group type: EXPERIMENTAL
Intervention: BITT + BoNT‐A
Number of subjects: 35
Study 25661064 — intervention group
Group type: EXPERIMENTAL
Intervention: BITT
Number of subjects: 35
Study 25661064 — intervention group
Group type: COMPARATOR
Intervention: BITT‐only
Number of subjects: 35
Study 25661064 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A + BITT
Number of subjects: 35